Table 3.
Sildenafil Effects on Resting Cardiovascular Function
| Placebo (n=25) | Sildenafil (n=23) | p | |
|---|---|---|---|
| Changes at 12 weeks | |||
| Δ HR (bpm) | 0 ± 10 | −2 ± 9 | 0.5 |
| Δ EDV (ml, n=22/18) | 3 ± 20 | 4 ± 20 | 0.9 |
| Changes at 24 weeks | |||
| Δ HR (bpm) | −1 ± 10 | −2 ± 10 | 0.6 |
| Δ EDV (ml, n=21/18) | 3 ± 19 | 12 ± 23 | 0.2 |
| Changes in vascular function, 12 weeks | |||
| Δ cSBP (mmHg, n=21/20) | 7 ± 17 | −9 ± 20 | 0.005 |
| Δ cAIx (%, n=21/20) | 1 ± 7 | −1 ± 10 | 0.4 |
| Δ Ea (mmHg/ml, n=23/18) | 0.08 ± 0.45 | −0.14 ± 0.25 | 0.17 |
| Δ SVR (dyne/s*cm5, n=23/18) | 73 ± 457 | −131 ± 300 | 0.2 |
| Δ TAC (ml/mmHg, n=19/15) | 0.01 ± 0.70 | 0.30 ± 0.60 | 0.3 |
| Δ RHI (n=16/12) | 0.05 ± 0.60 | 0.20 ± 0.51 | 0.5 |
| Δ PASP (mmHg, n=16/8) | −1 ± 8 | 0 ± 4 | 0.8 |
| Changes in vascular function, 24 weeks | |||
| Δ cSBP (mmHg, n=16/17) | 2 ± 16 | 1 ± 29 | 0.9 |
| Δ cAIx (%, n=16/17) | −1 ± 5 | 1 ± 11 | 0.6 |
| Δ Ea (mmHg/ml, n=22/18) | 0.02 ± 0.29 | −0.29 ± 0.28 | 0.008 |
| Δ SVR (dyne/s*cm5, n=22/18) | −27 ± 370 | −169 ± 375 | 0.4 |
| Δ TAC (ml/mmHg, n=15/15) | 0.04 ± 0.73 | 0.25 ± 0.61 | 0.7 |
| Δ RHI (n=15/14) | −0.17 ± 0.61 | 0.30 ± 0.45 | 0.054 |
| Δ PASP (mmHg, n=15/10) | 0 ± 6 | 3 ± 7 | 0.5 |
| Changes in LV systolic function, 12 weeks | |||
| Δ EF (%, n=24/22) | −1 ± 7 | 1 ± 4 | 0.08 |
| Δ SW/EDV (mmHg, n=22/18) | 0.6 ± 8.1 | −2.8 ± 4.5 | 0.2 |
| Δ PWR/EDV (mmHg/s, n=22/18) | 37 ± 80 | 18 ± 50 | 0.8 |
| Changes in LV systolic function, 24 weeks | |||
| Δ EF (%, n=23/21) | 0 ± 5 | 0 ± 4 | 0.95 |
| Δ SW/EDV (mmHg, n=21/18) | 0.3 ± 5.8 | −6.0 ± 5.1 | 0.006 |
| Δ PWR/EDV (mmHg/s, n=21/18) | 0 ± 40 | −52 ± 70 | 0.04 |
| Changes in LV diastolic function, 12 weeks | |||
| Δ E velocity (cm/s, n=24/20) | 1.7 ± 19 | 8.5 ± 18 | 0.3 |
| Δ DT (ms, n=22/19) | −4 ± 48 | 2 ± 38 | 0.7 |
| Δ E/A ratio (n=21/19) | −0.0 ± 0.5 | 0.2 ± 0.7 | 0.3 |
| Δ E′ (cm/s, n=24/19) | 0.1 ± 1.0 | 0.2 ± 1.0 | 0.9 |
| Δ E/E′ (n=23/19) | −0.0 ± 3.8 | 1.2 ± 3.8 | 0.3 |
| Changes in LV diastolic function, 24 weeks | |||
| Δ E velocity (cm/s, n=23/20) | −0.4 ± 19 | 12.5 ± 19 | 0.02 |
| Δ DT (ms, n=22/18) | −4 ± 39 | −8 ± 39 | 0.8 |
| Δ E/A ratio (20/18) | −0.0 ± 0.6 | 0.4 ± 0.8 | 0.07 |
| Δ E′ (cm/s, n=23/20) | −0.2 ± 0.0 | 0.4 ± 0.0 | 0.2 |
| Δ E/E′ (n=22/20) | 0.9 ± 4.9 | 1.9 ± 5.2 | 0.6 |
| Changes in Exercise Capacity, 12 weeks | |||
| Δ Peak VO2 (ml/min/kg) | −0.4 ± 1.5 | −0.7 ± 3.0 | 0.7 |
| Δ RER | 0.01 ± 0.08 | 0.02 ± 0.11 | 0.8 |
| Changes in Exercise Capacity, 24 weeks | |||
| Δ Peak VO2 (ml/min/kg, n=24/23) | −0.8 ± 1.7 | −0.6 ± 2.7 | 0.8 |
| Δ RER (n=23/23) | 0.01 ± 0.11 | 0.01 ± 0.11 | 0.5 |
Column 1 parentheses indicate number of placebo/sildenafil subjects with available data for each parameter; if no numbers are presented there was no data missing. P values are not adjusted for multiple comparisons.